RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
Thromb Haemost 2016; 115(02): 461-463
DOI: 10.1160/th15-05-0376
DOI: 10.1160/th15-05-0376
Letters to the Editor
Resveratrol: beneficial or not? Opposite effects of resveratrol on hypoxia-dependent PAI-1 expression in tumour and primary cells
Financial support: This work was supported by grants from Wilhelm Sander Foundation (Grant 2008 .043.1) to ED, Biocenter Oulu, Sigrid Juselius Foundation, and Finnish Academy of Sciences to TK.Weitere Informationen
Publikationsverlauf
Received:
05. Mai 2015
Accepted after major revision:
14. Juli 2015
Publikationsdatum:
22. November 2017 (online)
-
References
- 1 Delias C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
- 2 Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibri-nolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28: e72-91.
- 3 Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol 2012; 227: 493-507.
- 4 Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002; 48: 1194-1197.
- 5 Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 2008; 54: 1770-1779.
- 6 Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008; 100: 992-1006.
- 7 Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339: 1523-1526.
- 8 Hsieh TC, Wu JM. Resveratrol: Biological and pharmaceutical properties as anticancer molecule. Biofactors 2010; 36: 360-369.
- 9 Baur JA, Ungvari Z, Minor RK. et al. Are sirtuins viable targets for improving healthspan and lifespan?. Nat Rev Drug Discov 2012; 11: 443-461.
- 10 Carter LG, D’Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer 2014; 21: R209-225.
- 11 Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009; 11: 2851-2897.
- 12 Binder BR, Christ G, Gruber F. et al. Plasminogen activator inhibitor 1: physiological and patho-physiological roles. News Pysiol Sci 2002; 17: 56-61.
- 13 Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia inducible factor-1 in rat hepatocytes. Blood 1999; 94: 4177-4185.
- 14 Dimova EY, Moller U, Herzig S. et al. Transcrip-tional regulation of plasminogen activator in-hibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible fac-tor-1 in HepG2 cells. Thromb Haemost 2005; 93: 1176-1184.
- 15 Kortlever RM, Higgins PJ, Bernards R. Plasmi-nogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 08: 877-884.
- 16 Shetty S, Shetty P, Idell S. et al. Regulation of plas-minogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem 2008; 283: 19570-19580.
- 17 Samoylenko A, Roth U, Jungermann K. et al. The upstream stimulatory factor-2a inhibits plasmi-nogen activator inhibitor-1 gene expression by binding to a promoter element adjacent to the hy-poxia-inducible factor-1 binding site. Blood 2001; 97: 2657-2666.
- 18 Dimova EY, Kietzmann T. Cell type-dependent regulation of the hypoxia-responsive plasminogen activator inhibitor-1 gene by upstream stimulatory factor-2. J Biol Chem 2006; 281: 2999-3005.
- 19 Fukui M, Yamabe N, Kang KS. et al. Growth-stimulatory effect of resveratrol in human cancer cells. Mol Carcinog 2010; 49: 750-759.
- 20 Brakenhielm E, Cao R, Cao Y. Suppression of an-giogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001; 15: 1798-1800.
- 21 Rosenow A, Noben JP, Jocken J. et al. Resveratrol-induced changes of the human adipocyte secretion profile. J Proteome Res 2012; 11: 4733-4743.
- 22 Zagotta I, Dimova EY, Funcke JB. et al. Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue. Oxid Med Cell Longev 2013; 2013: 793525.
- 23 Ahn J, Lee H, Kim S. et al. Resveratrol inhibits TNF-alpha-induced changes of adipokines in 3T3-L1 adipocytes. Biochem Biophys Res Com-mun 2007; 364: 972-977.
- 24 Yen GC, Chen YC, Chang WT. et al. Effects of polyphenolic compounds on tumor necrosis factor-alpha (TNF-alpha)-induced changes of adipo-kines and oxidative stress in 3T3-L1 adipocytes. J Agric Food Chem 2011; 59: 546-551.
- 25 Olholm J, Paulsen SK, Cullberg KB. et al. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue ex-plants. Int J Obes 2010; 34: 1546-1553.
- 26 Xu F, Wang Y, Cui W. et al. Resveratrol Prevention of Diabetic Nephropathy Is Associated with the Suppression of Renal Inflammation and Mesangial Cell Proliferation: Possible Roles of Akt/NF-kap-paB Pathway. Int J Endocrinol 2014; 2014: 289327.
- 27 Suenaga F, Hatsushika K, Takano S. et al. A possible link between resveratrol and TGF-beta: resver-atrol induction of TGF-beta expression and signaling. FEBS Lett 2008; 582: 586-590.